The SF Business Times recently ran a feature about the VCs that could cash in from Bay Area biotech IPOs of the first half of the year.
“Stalwart VCs such as Kleiner Perkins Caufield & Byers of Menlo Park and Domain Associates are among the venture capital firms whose names pop up most often in the IPOs of local life sciences companies through June. Among the other VCs are DAG Ventures of Palo Alto and Essex Woodlands Health Ventures in Palo Alto.
In all, nine life sciences companies completed IPOs in the first half of the year, raising more than $600 million to help push through drugs through clinical trials or expand sales of their products. Another dozen are in the IPO queue.”
It includes a great graphic showing how the dollars flowed between startups and investors.